{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:04:43Z","timestamp":1787313883146,"version":"build-2736575974"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["259096"],"award-info":[{"award-number":["259096"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    miRNAs are involved in the development of metabolic associated fatty liver disease (MAFLD) and nonalcoholic steatohepatitis (NASH). We aimed to evaluate modifications by prolonged-release pirfenidone (PR-PFD) on key hepatic miRNAs expression in a MAFLD\/NASH model. First, male C57BL\/6J mice were randomly assigned into groups and fed with conventional diet (CVD) or high fat and carbohydrate diet (HFD) for 16\u00a0weeks. At the end of the eighth week, HFD mice were divided in two and only one half was treated with 300\u00a0mg\/kg\/day of PR-PFD mixed with food. Hepatic expression of miRNAs and target genes that participate in inflammation and lipid metabolism was determined by qRT-PCR and transcriptome by microarrays. Increased hepatic expression of miR-21a-5p, miR-34a-5p, miR-122-5p and miR-103-3p in MAFLD\/NASH animals was reduced with PR-PFD. Transcriptome analysis showed that 52 genes involved in lipid and collagen biosynthesis and inflammatory response were downregulated in PR-PFD group. The expression of\n                    <jats:italic>Il1b<\/jats:italic>\n                    ,\n                    <jats:italic>Tnfa<\/jats:italic>\n                    ,\n                    <jats:italic>Il6<\/jats:italic>\n                    ,\n                    <jats:italic>Tgfb1<\/jats:italic>\n                    ,\n                    <jats:italic>Col1a1<\/jats:italic>\n                    , and\n                    <jats:italic>Srebf1<\/jats:italic>\n                    were decreased in PR-PFD treated animals. MAFLD\/NASH animals compared to CVD group showed modifications in gene metabolic pathways implicated in lipid metabolic process, inflammatory response and insulin resistance; PR-PFD reversed these modifications.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-91187-2","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T06:15:03Z","timestamp":1622700903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD\/NASH"],"prefix":"10.1038","volume":"11","author":[{"given":"Rebeca","family":"Escutia-Guti\u00e9rrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Samael","family":"Rodr\u00edguez-Sanabria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Alejandra","family":"Monraz-M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Garc\u00eda-Ba\u00f1uelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Santos-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Sandoval-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Armend\u00e1riz-Borunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"91187_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"91187_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41575-020-0316-6","volume":"17","author":"H Tilg","year":"2020","unstructured":"Tilg, H. & Effenberger, M. From NAFLD to MAFLD: When pathophysiology succeeds. Nat. Rev. Gastroenterol. Hepatol. 17, 387\u2013388 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"91187_CR3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam, M., Sanyal, A. J. & George, J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158, 1999-2014.e1991 (2020).","journal-title":"Gastroenterology"},{"key":"91187_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.23280","volume":"51","author":"E Fabbrini","year":"2010","unstructured":"Fabbrini, E., Sullivan, S. & Klein, S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 51, 679\u2013689 (2010).","journal-title":"Hepatology"},{"key":"91187_CR5","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","volume":"23","author":"BJ Perumpail","year":"2017","unstructured":"Perumpail, B. J. et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J. Gastroenterol. 23, 8263\u20138276 (2017).","journal-title":"World J. Gastroenterol."},{"key":"91187_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11\u201320 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"91187_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes, C. & Razavi, H. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123\u2013133 (2018).","journal-title":"Hepatology"},{"key":"91187_CR8","first-page":"453","volume":"71","author":"J Lizardi-Cervera","year":"2006","unstructured":"Lizardi-Cervera, J., Laparra, D. I., Chavez-Tapia, N. C., Ostos, M. E. & Esquivel, M. U. Prevalence of NAFLD and metabolic syndrome in asymtomatics subjects. Rev. Gastroenterol. Mex. 71, 453\u2013459 (2006).","journal-title":"Rev. Gastroenterol. Mex."},{"key":"91187_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cgh.2015.05.001","volume":"14","author":"S Saab","year":"2016","unstructured":"Saab, S., Manne, V., Nieto, J., Schwimmer, J. B. & Chalasani, N. P. Nonalcoholic fatty liver disease in latinos. Clin. Gastroenterol. Hepatol. 14, 5\u201312 (2016) (quiz e19\u201310).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"91187_CR10","doi-asserted-by":"publisher","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","volume":"1","author":"EM Brunt","year":"2015","unstructured":"Brunt, E. M. et al. Nonalcoholic fatty liver disease. Nat. Rev. Dis. Primers 1, 15080 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"91187_CR11","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nrgastro.2013.87","volume":"10","author":"G Szabo","year":"2013","unstructured":"Szabo, G. & Bala, S. MicroRNAs in liver disease. Nat. Rev. Gastroenterol. Hepatol. 10, 542\u2013552 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"91187_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel, D. P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116, 281\u2013297 (2004).","journal-title":"Cell"},{"key":"91187_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11684-016-0468-5","volume":"10","author":"Z He","year":"2016","unstructured":"He, Z., Hu, C. & Jia, W. miRNAs in non-alcoholic fatty liver disease. Front Med. 10, 389\u2013396 (2016).","journal-title":"Front Med."},{"key":"91187_CR14","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s10620-015-4002-4","volume":"61","author":"G Szabo","year":"2016","unstructured":"Szabo, G. & Csak, T. Role of microRNAs in NAFLD\/NASH. Dig. Dis. Sci. 61, 1314\u20131324 (2016).","journal-title":"Dig. Dis. Sci."},{"key":"91187_CR15","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3390\/jcm4121953","volume":"4","author":"G Baffy","year":"2015","unstructured":"Baffy, G. MicroRNAs in nonalcoholic fatty liver disease. J. Clin. Med. 4, 1977\u20131988 (2015).","journal-title":"J. Clin. Med."},{"key":"91187_CR16","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","volume":"64","author":"CJ Pirola","year":"2015","unstructured":"Pirola, C. J. et al. Circulating microRNA signature in non-alcoholic fatty liver disease: From serum non-coding RNAs to liver histology and disease pathogenesis. Gut 64, 800\u2013812 (2015).","journal-title":"Gut"},{"key":"91187_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-nutr-081810-160756","volume":"31","author":"KJ Moore","year":"2011","unstructured":"Moore, K. J., Rayner, K. J., Su\u00e1rez, Y. & Fern\u00e1ndez-Hernando, C. The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu. Rev. Nutr. 31, 49\u201363 (2011).","journal-title":"Annu. Rev. Nutr."},{"key":"91187_CR18","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jhep.2014.10.004","volume":"62","author":"S Bandiera","year":"2015","unstructured":"Bandiera, S., Pfeffer, S., Baumert, T. F. & Zeisel, M. B. miR-122\u2014a key factor and therapeutic target in liver disease. J. Hepatol. 62, 448\u2013457 (2015).","journal-title":"J. Hepatol."},{"key":"91187_CR19","doi-asserted-by":"publisher","first-page":"13729","DOI":"10.1038\/srep13729","volume":"5","author":"J Ding","year":"2015","unstructured":"Ding, J. et al. Effect of miR-34a in regulating steatosis by targeting PPARalpha expression in nonalcoholic fatty liver disease. Sci. Rep. 5, 13729 (2015).","journal-title":"Sci. Rep."},{"key":"91187_CR20","doi-asserted-by":"publisher","first-page":"7466","DOI":"10.1038\/ncomms8466","volume":"6","author":"Y Xu","year":"2015","unstructured":"Xu, Y. et al. A metabolic stress-inducible miR-34a-HNF4alpha pathway regulates lipid and lipoprotein metabolism. Nat. Commun. 6, 7466 (2015).","journal-title":"Nat. Commun."},{"key":"91187_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3748\/wjg.v21.i2.511","volume":"21","author":"Q Xu","year":"2015","unstructured":"Xu, Q., Li, Y., Shang, Y.-F., Wang, H.-L. & Yao, M.-X. miRNA-103: Molecular link between insulin resistance and nonalcoholic fatty liver disease. World J. Gastroenterol. 21, 511\u2013516 (2015).","journal-title":"World J. Gastroenterol."},{"key":"91187_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nature10112","volume":"474","author":"M Trajkovski","year":"2011","unstructured":"Trajkovski, M. et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474, 649\u2013653 (2011).","journal-title":"Nature"},{"key":"91187_CR23","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1136\/gutjnl-2014-308883","volume":"65","author":"X Loyer","year":"2016","unstructured":"Loyer, X. et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARalpha expression. Gut 65, 1882\u20131894 (2016).","journal-title":"Gut"},{"key":"91187_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1582-4934.2008.00556.x","volume":"13","author":"AM Krichevsky","year":"2009","unstructured":"Krichevsky, A. M. & Gabriely, G. miR-21: A small multi-faceted RNA. J. Cell Mol. Med. 13, 39\u201353 (2009).","journal-title":"J. Cell Mol. Med."},{"key":"91187_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/ijms17091575","volume":"17","author":"A Caligiuri","year":"2016","unstructured":"Caligiuri, A., Gentilini, A. & Marra, F. Molecular pathogenesis of NASH. Int. J. Mol. Sci. 17, 20 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"91187_CR26","doi-asserted-by":"publisher","first-page":"172913","DOI":"10.1016\/j.ejphar.2020.172913","volume":"870","author":"M Ocker","year":"2020","unstructured":"Ocker, M. Challenges and opportunities in drug development for nonalcoholic steatohepatitis. Eur. J. Pharmacol. 870, 172913 (2020).","journal-title":"Eur. J. Pharmacol."},{"key":"91187_CR27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.dld.2004.05.012","volume":"36","author":"A Di Sario","year":"2004","unstructured":"Di Sario, A. et al. The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig. Liver Dis. 36, 744\u2013751 (2004).","journal-title":"Dig. Liver Dis."},{"key":"91187_CR28","doi-asserted-by":"publisher","first-page":"840","DOI":"10.7150\/ijms.11579","volume":"12","author":"DA Lopez-de la Mora","year":"2015","unstructured":"Lopez-de la Mora, D. A. et al. Role and new insights of pirfenidone in fibrotic diseases. Int. J. Med. Sci. 12, 840\u2013847 (2015).","journal-title":"Int. J. Med. Sci."},{"key":"91187_CR29","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1016\/S0168-8278(16)00367-6","volume":"64","author":"JLBR Poo","year":"2016","unstructured":"Poo, J. L. B. R. et al. Pharmacokinetics of the antifibrotic drug pirfenidone in Child-Pugh A and B cirrhotic patients compared to healthy age-matched controls. J. Hepatol. 64, S213\u2013S424 (2016).","journal-title":"J. Hepatol."},{"key":"91187_CR30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2337\/diacare.18.2.245","volume":"18","author":"DB Allison","year":"1995","unstructured":"Allison, D. B., Paultre, F., Maggio, C., Mezzitis, N. & Pi-Sunyer, F. X. The use of areas under curves in diabetes research. Diabetes Care 18, 245\u2013250 (1995).","journal-title":"Diabetes Care"},{"key":"91187_CR31","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews, D. R. et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412\u2013419 (1985).","journal-title":"Diabetologia"},{"key":"91187_CR32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","volume":"162","author":"P Chomczynski","year":"1987","unstructured":"Chomczynski, P. & Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156\u2013159 (1987).","journal-title":"Anal. Biochem."},{"key":"91187_CR33","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3, 1101\u20131108 (2008).","journal-title":"Nat. Protoc."},{"key":"91187_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12896-018-0421-6","volume":"18","author":"RAM Brown","year":"2018","unstructured":"Brown, R. A. M. et al. Total RNA extraction from tissues for microRNA and target gene expression analysis: Not all kits are created equal. BMC Biotechnol. 18, 16 (2018).","journal-title":"BMC Biotechnol."},{"key":"91187_CR35","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101\u20131108 (2008).","journal-title":"Nat. Protoc."},{"key":"91187_CR36","unstructured":"Unidad de Microarreglos de DNA-Instituto de Fisiolog\u00eda Celular, U. Microarreglos de rat\u00f3n, http:\/\/microarrays.ifc.unam.mx\/ (Updated)."},{"key":"91187_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"W da Huang","year":"2009","unstructured":"da Huang, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357 (2009).","journal-title":"Nat. Protoc."},{"key":"91187_CR38","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1136\/gutjnl-2014-308883","volume":"65","author":"X Loyer","year":"2016","unstructured":"Loyer, X. et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPAR\u03b1 expression. Gut 65, 1882\u20131894 (2016).","journal-title":"Gut"},{"key":"91187_CR39","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/hep.22569","volume":"48","author":"O Cheung","year":"2008","unstructured":"Cheung, O. et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48, 1810\u20131820 (2008).","journal-title":"Hepatology"},{"key":"91187_CR40","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12864-018-4575-3","volume":"19","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis. BMC Genom. 19, 188 (2018).","journal-title":"BMC Genom."},{"key":"91187_CR41","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1136\/gutjnl-2014-308430","volume":"65","author":"H Wu","year":"2016","unstructured":"Wu, H., Ng, R., Chen, X., Steer, C. J. & Song, G. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut 65, 1850\u20131860 (2016).","journal-title":"Gut"},{"key":"91187_CR42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3892\/ijmm.2015.2076","volume":"35","author":"C Sun","year":"2015","unstructured":"Sun, C. et al. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int. J. Mol. Med. 35, 847\u2013853 (2015).","journal-title":"Int. J. Mol. Med."},{"key":"91187_CR43","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/mnfr.201200182","volume":"56","author":"J Ahn","year":"2012","unstructured":"Ahn, J., Lee, H., Jung, C. H. & Ha, T. Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Mol. Nutr. Food Res. 56, 1665\u20131674 (2012).","journal-title":"Mol. Nutr. Food Res."},{"key":"91187_CR44","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1136\/gutjnl-2015-310822","volume":"65","author":"N Calo","year":"2016","unstructured":"Calo, N. et al. Stress-activated miR-21\/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption. Gut 65, 1871\u20131881 (2016).","journal-title":"Gut"},{"key":"91187_CR45","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/hep.26698","volume":"59","author":"L Yang","year":"2014","unstructured":"Yang, L. et al. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology 59, 483\u2013495 (2014).","journal-title":"Hepatology"},{"key":"91187_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fmed.2020.00020","volume":"7","author":"T Zhang","year":"2020","unstructured":"Zhang, T., Yang, Z., Kusumanchi, P., Han, S. & Liangpunsakul, S. Critical role of microRNA-21 in the pathogenesis of liver diseases. Front Med. 7, 20 (2020).","journal-title":"Front Med."},{"key":"91187_CR47","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00535-017-1404-4","volume":"53","author":"L Shang","year":"2018","unstructured":"Shang, L., Hosseini, M., Liu, X., Kisseleva, T. & Brenner, D. A. Human hepatic stellate cell isolation and characterization. J. Gastroenterol. 53, 6\u201317 (2018).","journal-title":"J. Gastroenterol."},{"key":"91187_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1152\/physrev.00013.2007","volume":"88","author":"SL Friedman","year":"2008","unstructured":"Friedman, S. L. Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88, 125\u2013172 (2008).","journal-title":"Physiol. Rev."},{"key":"91187_CR49","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/biomedicines9040365","volume":"9","author":"A Zisser","year":"2021","unstructured":"Zisser, A., Ipsen, D. H. & Tveden-Nyborg, P. Hepatic stellate cell activation and inactivation in NASH-fibrosis-roles as putative treatment targets?. Biomedicines 9, 365 (2021).","journal-title":"Biomedicines"},{"key":"91187_CR50","doi-asserted-by":"publisher","first-page":"44754","DOI":"10.1038\/srep44754","volume":"7","author":"C Komiya","year":"2017","unstructured":"Komiya, C. et al. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Sci. Rep. 7, 44754 (2017).","journal-title":"Sci. Rep."},{"key":"91187_CR51","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/hep4.1474","volume":"4","author":"A Sandoval-Rodriguez","year":"2020","unstructured":"Sandoval-Rodriguez, A. et al. pirfenidone is an agonistic ligand for PPAR\u03b1 and improves NASH by activation of SIRT1\/LKB1\/pAMPK. Hepatol. Commun. 4, 434\u2013449 (2020).","journal-title":"Hepatol. Commun."},{"key":"91187_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41420-018-0076-z","volume":"4","author":"PM Rodrigues","year":"2018","unstructured":"Rodrigues, P. M., Rodrigues, C. M. P. & Castro, R. E. Modulation of liver steatosis by miR-21\/PPAR\u03b1. Cell Death Discov. 4, 9 (2018).","journal-title":"Cell Death Discov."},{"key":"91187_CR53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","volume":"25","author":"JK Long","year":"2019","unstructured":"Long, J. K., Dai, W., Zheng, Y. W. & Zhao, S. P. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol. Med. 25, 26 (2019).","journal-title":"Mol. Med."},{"key":"91187_CR54","first-page":"505","volume":"3","author":"C Dorn","year":"2010","unstructured":"Dorn, C. et al. Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int. J. Clin. Exp. Pathol. 3, 505\u2013514 (2010).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"91187_CR55","doi-asserted-by":"publisher","first-page":"7466","DOI":"10.1038\/ncomms8466","volume":"6","author":"Y Xu","year":"2015","unstructured":"Xu, Y. et al. A metabolic stress-inducible miR-34a-HNF4\u03b1 pathway regulates lipid and lipoprotein metabolism. Nat. Commun. 6, 7466 (2015).","journal-title":"Nat. Commun."},{"key":"91187_CR56","doi-asserted-by":"publisher","first-page":"4168380","DOI":"10.1155\/2019\/4168380","volume":"2019","author":"LF Torres","year":"2019","unstructured":"Torres, L. F., Cogliati, B. & Otton, R. Green tea prevents NAFLD by modulation of miR-34a and miR-194 expression in a high-fat diet mouse model. Oxid. Med. Cell. Longev. 2019, 4168380 (2019).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"91187_CR57","doi-asserted-by":"publisher","first-page":"e0189223","DOI":"10.1371\/journal.pone.0189223","volume":"12","author":"C Baciu","year":"2017","unstructured":"Baciu, C. et al. Systematic integrative analysis of gene expression identifies HNF4A as the central gene in pathogenesis of non-alcoholic steatohepatitis. PLoS\u00a0One 12, e0189223 (2017).","journal-title":"PLoS\u00a0One"},{"key":"91187_CR58","doi-asserted-by":"publisher","first-page":"e12661","DOI":"10.14814\/phy2.12661","volume":"4","author":"J Soronen","year":"2016","unstructured":"Soronen, J. et al. Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease. Physiol. Rep. 4, e12661 (2016).","journal-title":"Physiol. Rep."},{"key":"91187_CR59","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1440-1746.2011.06864.x","volume":"27","author":"X Jin","year":"2012","unstructured":"Jin, X. et al. Transition from hepatic steatosis to steatohepatitis: Unique microRNA patterns and potential downstream functions and pathways. J. Gastroenterol. Hepatol. 27, 331\u2013340 (2012).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"91187_CR60","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/nu9040360","volume":"9","author":"A Gracia","year":"2017","unstructured":"Gracia, A. et al. Are miRNA-103, miRNA-107 and miRNA-122 involved in the prevention of liver steatosis induced by resveratrol?. Nutrients 9, 360 (2017).","journal-title":"Nutrients"},{"key":"91187_CR61","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1872-034X.2008.00382.x","volume":"38","author":"N Higuchi","year":"2008","unstructured":"Higuchi, N. et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol. Res. 38, 1122\u20131129 (2008).","journal-title":"Hepatol. Res."},{"key":"91187_CR62","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3350\/cmh.2013.19.3.210","volume":"19","author":"S-H Koo","year":"2013","unstructured":"Koo, S.-H. Nonalcoholic fatty liver disease: Molecular mechanisms for the hepatic steatosis. Clin. Mol. Hepatol. 19, 210\u2013215 (2013).","journal-title":"Clin. Mol. Hepatol."},{"key":"91187_CR63","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","volume":"75","author":"DH Ipsen","year":"2018","unstructured":"Ipsen, D. H., Lykkesfeldt, J. & Tveden-Nyborg, P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol. Life Sci. 75, 3313\u20133327 (2018).","journal-title":"Cell Mol. Life Sci."},{"key":"91187_CR64","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0168-8278(02)00272-6","volume":"37","author":"L Garcia","year":"2002","unstructured":"Garcia, L. et al. Pirfenidone effectively reverses experimental liver fibrosis. J. Hepatol. 37, 797\u2013805 (2002).","journal-title":"J. Hepatol."},{"key":"91187_CR65","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/j.1440-1681.2009.05194.x","volume":"36","author":"XY Zhao","year":"2009","unstructured":"Zhao, X. Y., Zeng, X., Li, X. M., Wang, T. L. & Wang, B. E. Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. Clin. Exp. Pharmacol. Physiol. 36, 963\u2013968 (2009).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"91187_CR66","first-page":"20","volume":"20","author":"J Guti\u00e9rrez-Cuevas","year":"2020","unstructured":"Guti\u00e9rrez-Cuevas, J. et al. Prolonged-release pirfenidone prevents obesity-induced cardiac steatosis and fibrosis in a mouse NASH model. Cardiovasc. Drugs Ther. 20, 20 (2020).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"91187_CR67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12944-017-0572-9","volume":"16","author":"Z Chen","year":"2017","unstructured":"Chen, Z., Yu, R., Xiong, Y., Du, F. & Zhu, S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 16, 203\u2013203 (2017).","journal-title":"Lipids Health Dis."},{"key":"91187_CR68","doi-asserted-by":"publisher","first-page":"9547613","DOI":"10.1155\/2018\/9547613","volume":"2018","author":"M Masarone","year":"2018","unstructured":"Masarone, M., Rosato, V., Dallio, M. & Gravina, A. G. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid. Med. Cell Longev. 2018, 9547613 (2018).","journal-title":"Oxid. Med. Cell Longev."},{"key":"91187_CR69","first-page":"145","volume":"16","author":"K Kazankov","year":"2019","unstructured":"Kazankov, K. & J\u00f8rgensen, S. M. D. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat. Rev. 16, 145\u2013159 (2019).","journal-title":"Nat. Rev."},{"key":"91187_CR70","first-page":"100","volume":"6","author":"J Grunhut","year":"2018","unstructured":"Grunhut, J. et al. Macrophages in nonalcoholic steatohepatitis: Friend or foe?. Eur. Med. J. Hepatol. 6, 100\u2013109 (2018).","journal-title":"Eur. Med. J. Hepatol."},{"key":"91187_CR71","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41374-019-0255-4","volume":"99","author":"G Chen","year":"2019","unstructured":"Chen, G., Ni, Y. & Nagata, N. Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages. Lab. Invest. 99, 1335\u20131348 (2019).","journal-title":"Lab. Invest."},{"key":"91187_CR72","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5114\/ceji.2018.77395","volume":"43","author":"M Kosmalski","year":"2018","unstructured":"Kosmalski, M., Mokros, \u0141, Kuna, P., Witusik, A. & Pietras, T. Changes in the immune system\u2014the key to diagnostics and therapy of patients with non-alcoholic fatty liver disease. Cent. Eur. J. Immunol. 43, 231\u2013239 (2018).","journal-title":"Cent. Eur. J. Immunol."},{"key":"91187_CR73","first-page":"631","volume":"16","author":"M Nakamuta","year":"2005","unstructured":"Nakamuta, M. et al. Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int. J. Mol. Med. 16, 631\u2013635 (2005).","journal-title":"Int. J. Mol. Med."},{"key":"91187_CR74","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejphar.2008.06.110","volume":"595","author":"A Salazar-Montes","year":"2008","unstructured":"Salazar-Montes, A., Ruiz-Corro, L., Lopez-Reyes, A., Castrejon-Gomez, E. & Armendariz-Borunda, J. Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur. J. Pharmacol. 595, 69\u201377 (2008).","journal-title":"Eur. J. Pharmacol."},{"key":"91187_CR75","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12890-017-0405-7","volume":"17","author":"Y Liu","year":"2017","unstructured":"Liu, Y., Lu, F., Kang, L., Wang, Z. & Wang, Y. Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2\/Bach1 equilibrium. BMC Pulm. Med. 17, 63 (2017).","journal-title":"BMC Pulm. Med."},{"key":"91187_CR76","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","volume":"52","author":"AP Rolo","year":"2012","unstructured":"Rolo, A. P., Teodoro, J. S. & Palmeira, C. M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 52, 59\u201369 (2012).","journal-title":"Free Radic. Biol. Med."},{"key":"91187_CR77","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3390\/nu11040799","volume":"11","author":"G Palladini","year":"2019","unstructured":"Palladini, G. et al. Fatty acid desaturase involvement in non-alcoholic fatty liver disease rat models: Oxidative stress versus metalloproteinases. Nutrients 11, 799 (2019).","journal-title":"Nutrients"},{"key":"91187_CR78","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/antiox10020174","volume":"10","author":"JC Arroyave-Ospina","year":"2021","unstructured":"Arroyave-Ospina, J. C., Wu, Z. & Geng, Y. Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: Implications for prevention and therapy. Antioxidants 10, 174 (2021).","journal-title":"Antioxidants"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91187-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91187-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91187-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T04:04:21Z","timestamp":1670040261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91187-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91187"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91187-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"27 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Juan Armendariz-Borunda is a consultant for Cell Pharma S.A. de C.V. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11709"}}